



CNMV  
Markets Directorate General  
C/ Edison núm. 4  
28006 Madrid

Madrid, June 3<sup>rd</sup> 2024

In accordance with article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, articles 2.2 and 2.3 of the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation measures and concordant provisions, is hereby reported the following

### **OTHER RELEVANT INFORMATION**

#### **Share buy-back, stabilisation and treasury stock programmes**

In relation to the program to buy-back treasury shares announced by means of other relevant information communication dated April 30, 2024 (registration number 28360) (the "**Buy-back Program**"), Pharma Mar, S.A. informs that during the period from 27 May to 31 May 2024 it has not carried out any transactions under the Buy-back Program.